


Quality Assurance Report

TTUHSC Breast Center of Excellence

January 1, 2009 – December 31, 2009



Stage Distribution

Total Number of Patients = 106

Time Frame	Stage 0	Stage I	Stage II	Stage III	Stage IV	Stage Unassigned	Total
Jan – Jun	4 (8.5%)	13 (27.6%)	20 (42.5%)	8 (17.0%)	2 (4.25%)	-	47 (100%)
Jul - Dec	8 (16.5%)	22 (37.2%)	20 (33.8%)	6 (10.1%)	-	3 (5.0%)	59 (100%)
Jan-Dec	12 (11.3%)	35 (33.0%)	40 (37.7%)	14 (13.2%)	2 (1.8%)	3 (2.8%)	106 (100%)

Mode of Diagnosis

Total Number of Patients = 106

Time Frame	Stage 0	Stage I	Stage II	Stage III	Stage IV	Stage Unassigned	Total
Jan – Jun Preoperative Core	4 (8.5%)	13 (27.6%)	20 (42.5%)	8 (17.0%)	2 (4.25%)	-	47 (100%)
Jul – Dec Preoperative Core	8 (16.5%)	22 (37.2%)	20 (33.8%)	6 (10.1%)	-	3 (5.0%)	59 (100%)
Jan-Dec Preoperative Core	12 (11.3%)	35 (33.0%)	40 (37.7%)	14 (13.2%)	2 (1.8%)	3 (2.8%)	106 (100%)

100% of patients had diagnosis established on preoperative core needle biopsy

Tumor Board Discussion

Total Number of Patients = 106

Time Frame	Stage 0	Stage I	Stage II	Stage III	Stage IV	Stage Unassigned	Total
Jan – Jun Discussed	3/4 (75.0%)	12/13 (92.3%)	15/20 (75.0%)	7/8 (87.5%)	2/2 (100%)	-	39/47 (82.9%)
Jul – Dec Discussed	5/8 (62.5%)	13/22 (59.0%)	16/20 (80.0%)	4/6 (66.6%)	-	2/3 (66.6%)	40/59 (67.8%)
Jan-Dec Discussed	8/12 (66.6%)	25/35 (71.4%)	31/40 (77.5)	11/14 (78.5%)	2/2 (100%)	2/3 (66.6%)	79/106 (74.5%)

74.5% of patients were discussed prospectively in the multidisciplinary tumor conference

Multidisciplinary Assessment (Surgical, Medical and Radiation Oncologist)

Total Number of Patients = 106

Time Frame	Stage 0	Stage I	Stage II	Stage III	Stage IV	Stage Unassigned	Total
Jan – Jun MDC seen	2/4 (50.0%)	8/13 (61.4%)	12/20 (60.0%)	7/8 (87.5%)	1/2 (50.0%)	-	30/47 (63.8%)
Jul – Dec MDC seen	4/8 (50.0%)	15/22 (68.1%)	14/20 (70.0%)	6/6 (100%)	-	2/3 (66.6%)	41/59 (69.4%)
Jan-Dec MDC seen	8/12 (66.6%)	23/35 (65.7%)	26/40 (65.0%)	13/14 (92.8%)	1/2 (100%)	2/3 (66.6%)	71/106 (66.9%)

Exceptions

35/106 (33.0%)

- No radiation oncology evaluation (mast./ high-risk)
- No documentation in the chart
- Patient non-compliance

31/35 (88.5%)

2/35 (5.7%)

2/35 (5.7%)

Nurse Navigation

Total Number of Patients = 106

Time Frame	Stage 0	Stage I	Stage II	Stage III	Stage IV	Stage Unassigned	Total
Jan – Jun Assigned	3/4 (75.0%)	12/13 (92.3%)	20/20 (100%)	8/8 (100%)	2/2 (100%)	-	45/47 (95.7%)
Jul – Dec Assigned	6/8 (75.0%)	20/22 (90.9%)	19/20 (95.0%)	6/6 (100%)	-	3/3 (100%)	54/59 (91.5%)
Jan-Dec Assigned	9/12 (75.0%)	32/35 (91.4%)	39/40 (97.5%)	14/14 (100%)	2/2 (100%)	3/3 (100%)	99/106 (93.3%)

Exceptions

7/106 (6.6%)

•Lateral entry into the system

7/7 (100%)*

* modifications made to ensure assignment of a nurse navigator for every patient

CAP Compliance

Total Number of Patients = 106

Time Frame	Stage 0	Stage I	Stage II	Stage III	Stage IV	Stage Unassigned	Total
Jan – Jun Yes	2/4 (50.0%)	13/13 (100%)	20/20 (100%)	8/8 (100%)	1/2 (50.0%)	-	44/47 (93.6%)
Jul – Dec Yes	2/8 (25.0%)	22/22 (100%)	20/20 (100%)	6/6 (100%)	-	1/2 (33.3%)	51/59 (86.4)
Jan-Dec Yes	4/12 (33.3%)	35/35 (100%)	40/40 (100%)	14/14 (100%)	1/2 (50.0%)	1/3 (33.3%)	95/106 (89.6%)

Exceptions

11/106 (10.3%)

- Progesterone receptor not reported
- Final surgery not done yet (neoadjuvant)

8/11 (72.7%)

3/11 (27.2%)

Axillary Staging

Total Number of Patients = 106

Total Number of Patients with Invasive Cancer = 94

- Number node positive patients on needle biopsy 16/94 (17.0%)
- Number of patients eligible for SLNB 78/94 (82.9%)
 - Number of patients with SLNB 72/78 (92.3%)
- Exceptions 6/78 (7.6%)
 - Determined low risk (unlikely to change treatment plan) 5/6 (83.3%)
 - Stage IV disease documented 1/6 (16.6%)

Axillary Dissection

Total Number of Patients = 106

Total Number of Patients with Invasive Cancer = 94

- Number of Patients with node positive disease 42/94 (44.6%)
- Number of patients eligible for ALND 42
 - Number of patients with ALND 28/42 (66.6%)
- Exceptions **14/42 (33.3%)**
 - Low risk for non-SLN mets. on MSKCC nomogram 13/14 (92.8%)
 - Patient refused completion ALND 1/14 (7.1)

Breast Conservation

Total Number of Patients = 106

Time Frame	Stage 0	Stage I	Stage II	Stage III	Stage IV	Stage Unassigned	Total
Jan – Jun Yes	2/4 (50.0%)	11/13 (84.6%)	13/20 (65.0%)	4/8 (50.0%)	2/2 (100%)	-	30/47 (63.8%)
Jul – Dec Yes	4/8 (50.0%)	15/22 (68.1%)	13/20 (65.0%)	1/6 (16.6%)	-	1/3 (33.3%)	34/59 (57.6%)
Jan-Dec Yes	6/12 (50.0%)	26/35 (74.2%)	26/40 (65%)	5/14 (35.7%)	2/2 (100%)	1/3 (33.3%)	64/106 (60.3%)

Number of early stage patients (0,I and II) with breast conservation **58/87 (66.6%)**

Post-lumpectomy Radiation

Total Number of Patients = 106

- Number of patients with lumpectomy 64/106 (60.3%)
- Number of patients eligible for Radiation 64
 - Number of patients radiated 48/64 (75%)
- Exceptions **16/64 (25%)**
 - Low risk malignancy
 - age group 75 – 93 years
 - severe co morbidities
- Number of patients radiated within 12 months **48/48 (100%)**

Post-Mastectomy Radiation

Total Number of Patients = 106

- Number of patients with mastectomy 39/106 (36.7%)
- Number eligible for radiation ($\geq T3$ or $\geq N2$) 10/39 (25.6%)
 - Number of patients radiated 10/10 (100%)
- Exceptions **0 (none)**
- Number of patients radiated within 12 months **10/10 (100%)**

Systemic Chemotherapy - I

Total Number of Patients = 106

- ER negative patients with invasive cancer 26/106 (24.5%)
 - Number eligible for chemotherapy (exclude DCIS) 22/26 (84.6%)
 - Number treated with chemotherapy 20/22 (90.9%)
 - Exceptions 2/22 (9.2%)
 - Patient refused (1 stage II, 1 stage III) 2/2 (100%)

- Number with chemotherapy within 4 months 19/20 (95.0%)
 - Exceptions 1/20 (0.05%)
 - Patient non-compliance (stage II) 1/1 (100%)

Systemic Chemotherapy - II

Total Number of Patients = 106

- ☐ ER positive patients with invasive cancer 74/106 (69.8%)
 - Number treated with chemotherapy 26 /74 (35.1%)

- ☐ Number with chemotherapy within 4 months **23/26 (88.4%)**
 - Exceptions **3/26 (11.5%)**
 - Patient non-compliance (stage II) 1/3 (33.3%)
 - Postop. wound complications (1 stage I, 1 stage II) 2/3 (66.6%)

Systemic Endocrine Therapy

Total Number of Patients = 106

- ☐ Number of ER positive patients 80/106 (75.4%)
 - Number treated with endocrine therapy 64 /80 (80.0%)
 - Exceptions 16/80 (20.0%)
 - Determined risk > benefit 2/16 (12.5%)
 - No documentation in the chart 1/16 (6.25%)
 - Patient non-compliance 13/16 (81.25%)
- ☐ Number with endocrine therapy within 1 year 64/64 (100%)

Rehabilitation

Total Number of Patients = 106

- Number enrolled in CPRP (PT/OT) 28/106 (29.68%)
- Number enrolled in CPRP (Psycho-oncology) 0

- Exceptions 78/106 (70.32%)

Services were available but structured program is recently put in place, whereby every patient gets a baseline arm girth and shoulder range of motion documented; prospective data is maintained with a pre-designed schedule.

Genetic Counseling

Total Number of Patients = 106

- Number of patients with family history or < 45 years 49/106 (46.2%)
- Number received genetic counseling **16/49 (32.6%)**
 - Number tested 6/33 (18.1%)
 - Positive 2/6 (33.3%)
 - Negative 4/6 (66.6%)
 - Number refused testing 10 (20.4%)
- Exceptions **33/49 (67.3%)**
 - Did not meet NCCN criteria 29/33 (87.8%)
 - No documentation in the chart 2/33 (6.0%)
 - patient non-compliance 2/33 (6.0%)

Trial Participation

Total Number of Patients = 106

Time Frame	Trial / Study	Eligible N (%)	Participation N (%)
Jan – Jun	07132	-	-
	B-SMART	-	-
	SPOC	-	-
	SWOG S0307	2 (4.26%)	2 (4.26%)
Total		2 (4.26%)	2 (4.26%)
Jul - Dec	07132	1 (1.6%)	1 (1.6%)
	B-SMART	7 (11.8%)	7 (11.8%)
	SPOC	1 (1.6%)	1 (1.6%)
	SWOG S0307	5 (8.4%)	4 (6.7%)
Total		14 (23.7%)	13 (22.0%)

Total Number of patients enrolled in trials in 2009

15/106 (14.1%)